CAMYLOFIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

The global camylofin market has been facing a major challenge due to the patent expiry of blockbuster drugs in recent times. Several top-selling drugs including Lipitor, Diovan, Plavix, and Nexium lost patent protection between 2011 to 2015, resulting in more generics entering the market. This has led to an erosion in sales for innovative drugs in the range of 25-50%. As major drugs contributing significantly to the revenue of big pharmaceutical companies got out of patents, it caused a sales decline and loss of market share. The companies have found it difficult to replace the revenues with new drugs launches alone. This patent cliff has put immense financial pressure on research and development activities of companies in this market.

Market Opportunity: Strategic collaborations and partnerships for market

Strategic collaborations and partnerships provide a major opportunity for growth in the global camylofin market. As individual companies find it challenging to tackle increasing development costs and bring novel therapies to market alone, partnering has become crucial. Alliances allow companies to leverage each other's core competencies, skills, and resources. This helps reduce risks and fast-tracks the development of new drugs. Many companies in this market have formed agreements for research, development, marketing and distribution to expand their geographic footprint and product portfolio. Such cooperative deals enable companies to gain access to new technologies, licenses, late-stage assets and consumer bases. This opportunity, if tapped properly through win-win partnerships, can drive market expansion in coming years.